Establishment and Application of 3-Dimensional (3-D) Cell Culture Model of Clinical Circulating Tumor Cells (CTCs)

November 12, 2023 updated by: Chang Gung Memorial Hospital

The goal of this observational study is to validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion in cancer patient with transitional cell carcinoma and patient without cancer.

This project first aims to study the clinical feasibility of utilizing a 3-D cell culture model for the isolation/purification of all possible CTCs in a blood sample in a label-free, viable, and high-purity manner. Through 3-D CTC culture, moreover, the cell number of CTCs can be adequately expanded. All these advantageous features are beyond what is currently possible by using the existing methods. In addition, the harvest of CTCs with above features is found valuable for the subsequent academic researches or clinical studies (e.g. molecular mechanisms underlying cancer metastasis, cancer-related gene mutation, biomarker discovery, and particularly CTCs-based chemotherapy drug testing). These could both facilitate and accelerate scientists to develop new therapeutic solutions for future cancer care.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Circulating tumor cells (CTCs), the rare cell species present in the blood, are considered to mainly contribute to cancer metastasis or relapse. Thus, the detection of CTCs is regarded as an essential clinical tool to detect metastatic cancer. Moreover, CTCs can be the therapeutic target of metastatic cancer care. Therefore, the use of viable CTCs as a biopsy to select therapeutic regimens (e.g. CTCs-based anti-cancer drug testing) opens up a promising route to realize personalized cancer therapy. With the recent advances in cell isolation or detection techniques, various novel approaches have been actively proposed to isolate/detect CTCs. Nevertheless, most of current methods might not be able to obtain the all possible, viable, and label-free CTCs with adequate cell purity and cell number for the subsequent CTCs-based anti-cancer drug testing or other bioassays. To tackle the above technical hurdles, the research project proposes the use of a specific 3-D cell culture technique for the isolation/purification, and cell number expansion of CTCs.

The working principle is based on our preliminary findings showing that the human leukocytes will die away in 3-D cell culture condition, whereas the CTCs will tend to aggregate and proliferate in such environment. Based on this phenomenon, the 3-D CTC cell culture can be used to isolate and purify the viable CTCs from the leukocyte background in a negative selection, and label-free manner, enabling the harvest of the all possible CTCs in a blood sample. Furthermore, the proliferation of CTCs in such 3-D cell culture can adequately expand the cell number of CTCs for the subsequent applications, which is currently impossible using the existing methods.

In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion. In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation. In the optimization process, investigators will explore the effect of cell culture model (e.g. static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g. glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC solation/purification and proliferation. As a whole, investigators hope the proposed research project can find out an efficient and effective approach to isolate/purify/expand clinical CTCs in a viable, label-free, and high-purity manner. These harvested CTCs are valuable for the subsequent analytical tasks.

Study Type

Observational

Enrollment (Estimated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

cancer patients with transitional cell carcinoma

Description

Inclusion Criteria:

  1. patients who agreed with the content of informed consent of the study protocol
  2. patients who agreed the researcher to review the medical record
  3. adults >20 years old
  4. Patients have the right to asked withdrawing from the trial at any timepoints
  5. meet the following requirements (1)cancer participants:cancer patients with transitional cell carcinoma (2)healthy participants:participants without cancer

Exclusion Criteria:

  1. Patients who refused the collection of blood and the reviewing of medical record
  2. The investigators suggest to withdraw

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Cancer for CTC culture
participants are cancer patients with transitional cell carcinoma
In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion. In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation. In the optimization process, investigators will explore the effect of cell culture model (e.g. static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g. glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC isolation/purification and proliferation.
Healthy for CTC culture
enroll participants without cancer
In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion. In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation. In the optimization process, investigators will explore the effect of cell culture model (e.g. static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g. glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC isolation/purification and proliferation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the effect of cell culture model for the Cell viability
Time Frame: 3 month
optimize the 3-D cell culture model to measure the Cell viability
3 month
the effect of cell culture model for the Cell viability
Time Frame: 6 month
optimize the 3-D cell culture model to measure the Cell viability
6 month
the effect of cell culture model for the Cell number
Time Frame: 3 month
optimize the 3-D cell culture model to measure the Cell number
3 month
the effect of cell culture model for the Cell number
Time Frame: 6 month
optimize the 3-D cell culture model to measure the Cell number
6 month
the effect of cell culture model for the Cell viability
Time Frame: baseline
optimize the 3-D cell culture model to measure the Cell viability
baseline
the effect of cell culture model for the Cell number
Time Frame: baseline
optimize the 3-D cell culture model to measure the Cell number
baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the effect of biochemical factors for glucose concentration
Time Frame: baseline, pre-intervention
investigate the effect of of biochemical factors to measure glucose concentration
baseline, pre-intervention
the effect of biochemical factors for glucose concentration
Time Frame: 3 month
investigate the effect of of biochemical factors to measure glucose concentration
3 month
the effect of biochemical factors for glucose concentration
Time Frame: 6 month
investigate the effect of of biochemical factors to measure glucose concentration
6 month
the effect of biochemical factors for the serum concentration of growth factors/cytokines
Time Frame: baseline, pre-intervention
investigate the effect of of biochemical factors to measure the serum concentration of growth factors/cytokines
baseline, pre-intervention
the effect of biochemical factors for the serum concentration of growth factors/cytokines
Time Frame: 3 month
investigate the effect of of biochemical factors to measure the serum concentration of growth factors/cytokines
3 month
the effect of biochemical factors for the serum concentration of growth factors/cytokines
Time Frame: 6 month
investigate the effect of of biochemical factors to measure the serum concentration of growth factors/cytokines
6 month
the effect of biochemical factors for the serum pH
Time Frame: 3 month
investigate the effect of of biochemical factors to measure the serum pH
3 month
the effect of biochemical factors for the serum pH
Time Frame: 6 month
investigate the effect of of biochemical factors to measure the serum pH
6 month
the effect of biochemical factors for the serum pH
Time Frame: baseline
investigate the effect of of biochemical factors to measure the serum pH
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Hsuan-Chih Kuo, Ye,Siou-Ru

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 31, 2021

Primary Completion (Estimated)

May 31, 2024

Study Completion (Estimated)

May 31, 2024

Study Registration Dates

First Submitted

November 7, 2022

First Submitted That Met QC Criteria

November 16, 2022

First Posted (Actual)

November 21, 2022

Study Record Updates

Last Update Posted (Estimated)

November 14, 2023

Last Update Submitted That Met QC Criteria

November 12, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cell Carcinoma

Clinical Trials on CTCs isolation/purification and cell number expansion

3
Subscribe